Minoxidil May Safely Aid in Hair Growth for Patients With Breast Cancer ...

Datroway (datopotamab deruxtecan-dlnk) is a treatment for adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who have previously ... With these approvals, ...

AstraZeneca and Daiichi Sankyo withdrew an application in the European Union for the drug to treat a type of lung cancer in December following feedback from regulatory advisers. Mixed results from ...

AstraZeneca and Daiichi's first co-developed ADC, Enhertu, was first approved by the FDA in 2019 for a type of breast cancer and later expanded for use in multiple conditions. In December ...

Dr Mimi Huizinga is Vice President, Oncology Medical Affairs, Lung Cancer at AstraZeneca. She focuses on improving healthcare by achieving clinical excellence and amplifying scientific innovation ...

The UAB Department of Radiation Oncology is an integral part of one of the nation's largest health systems. Nationally known for our compassionate care, cutting-edge research, and comprehensive ...

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said ... whose disease has become resistant to current treatments.” Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo, said, ...

These make five multifamily deals north of $100M we've reported on in just the last few weeks. Sentinel Real Estate Corp. recently bought two big apartment communities in Tysons and Gaithersburg ...

Copies of AstraZeneca Plc’s Calquence tablets proposed by MSN Laboratories Pvt. Ltd. infringe two patents for the blood-cancer treatment, according to a federal lawsuit filed six months after MSN ...

AstraZeneca’s business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases, vaccines and other.

After several years of growing expectation, AstraZeneca’s long-awaited MYSTIC immune-oncology trial has failed to show benefit over standard lung cancer therapy. The combination of two different ...